ATE104698T1 - Influenza-impfstoff. - Google Patents

Influenza-impfstoff.

Info

Publication number
ATE104698T1
ATE104698T1 AT8888300951T AT88300951T ATE104698T1 AT E104698 T1 ATE104698 T1 AT E104698T1 AT 8888300951 T AT8888300951 T AT 8888300951T AT 88300951 T AT88300951 T AT 88300951T AT E104698 T1 ATE104698 T1 AT E104698T1
Authority
AT
Austria
Prior art keywords
vaccine
strain
cell
influenza vaccine
influenza
Prior art date
Application number
AT8888300951T
Other languages
English (en)
Inventor
John Sydney Oxford
James Searl Robertson
Geoffrey Christopher Schild
David Arthur John Tyrrell
Original Assignee
British Tech Group
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Tech Group filed Critical British Tech Group
Application granted granted Critical
Publication of ATE104698T1 publication Critical patent/ATE104698T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT8888300951T 1987-02-18 1988-02-04 Influenza-impfstoff. ATE104698T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB878703696A GB8703696D0 (en) 1987-02-18 1987-02-18 Influenza vaccine
EP88300951A EP0279563B1 (de) 1987-02-18 1988-02-04 Influenza-Impfstoff

Publications (1)

Publication Number Publication Date
ATE104698T1 true ATE104698T1 (de) 1994-05-15

Family

ID=10612471

Family Applications (1)

Application Number Title Priority Date Filing Date
AT8888300951T ATE104698T1 (de) 1987-02-18 1988-02-04 Influenza-impfstoff.

Country Status (9)

Country Link
US (1) US5162112A (de)
EP (1) EP0279563B1 (de)
JP (1) JP2525734B2 (de)
AT (1) ATE104698T1 (de)
AU (1) AU613012B2 (de)
CA (1) CA1335790C (de)
DE (1) DE3889138T2 (de)
ES (1) ES2052699T3 (de)
GB (2) GB8703696D0 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374717A (en) * 1992-09-30 1994-12-20 The United States Of America As Represented By The Secretary Of Health And Human Services Sequences of the hemagglutinins of recent strains of influenza type B virus
AU7104194A (en) * 1993-06-11 1995-01-03 Peter Palese High yielding influenza viruses
FR2761698B1 (fr) * 1997-04-04 1999-05-07 Pasteur Merieux Serums Vacc Methode de titrage d'une composition virale complexe
WO2006033691A2 (en) * 2004-07-02 2006-03-30 Niman Henry L Copy choice recombination and uses thereof
US7468187B2 (en) * 2005-10-18 2008-12-23 Iowa State University Research Foundation, Inc. Canine influenza virus and related compositions and methods of use
ATE494906T1 (de) 2005-11-01 2011-01-15 Novartis Vaccines & Diagnostic Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna
JP5603012B2 (ja) 2005-12-02 2014-10-08 トヘ モウント シナイ スクール オフ メディシネ オフ ニューヨーク ウニベルシトイ 非天然表面タンパク質を提示するキメラウイルス及びその使用
NZ575271A (en) 2006-09-11 2011-09-30 Novartis Ag Making influenza virus vaccines without using eggs
JP2011506264A (ja) * 2006-12-06 2011-03-03 ノバルティス アーゲー インフルエンザウイルスの４つの株に由来する抗原を含むワクチン
EP2170382B1 (de) * 2007-06-15 2013-07-31 Protheon Co., Ltd. Lebendimpfstoff einen attenuierten influenzavirus enthaltend
EP2235532B1 (de) * 2007-12-24 2013-04-24 Novartis AG Testverfahren für adsorbierte grippeimpfstoffe
EA023662B1 (ru) 2009-02-10 2016-06-30 Новартис Аг Вакцины против гриппа со сниженным количеством сквалена
US20110110975A1 (en) * 2009-11-06 2011-05-12 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
EP2566958B1 (de) * 2010-05-03 2015-12-30 GlaxoSmithKline Biologicals S.A. Verfahren zur inaktivierung des influenza-virus
US9821051B1 (en) 2010-10-28 2017-11-21 Seqirus UK Limited Reducing hospitalization in elderly influenza vaccine recipients
CA2826234A1 (en) * 2010-11-02 2012-05-10 Hector Manuel Zepeda Lopez Novel vaccines against the a/h1n1 pandemic flu virus
EP2704740B1 (de) 2011-05-04 2016-10-05 Streck, Inc. Inaktiviertes schweinegrippe-virus und verfahren zu seiner herstellung
US9579374B2 (en) * 2013-12-04 2017-02-28 The Johns Hopkins University Method for rapidly designing pharmaceutical preparations for preventing viral infection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE662899A (de) * 1964-04-22
US4040905A (en) * 1971-10-27 1977-08-09 The United States Government Sub-human primate diploid cell lines as substrates for virus vaccine production

Also Published As

Publication number Publication date
GB2202327A (en) 1988-09-21
US5162112A (en) 1992-11-10
EP0279563B1 (de) 1994-04-20
AU1191188A (en) 1988-08-25
GB2202327B (en) 1991-05-15
DE3889138D1 (de) 1994-05-26
EP0279563A2 (de) 1988-08-24
AU613012B2 (en) 1991-07-25
GB8703696D0 (en) 1987-03-25
CA1335790C (en) 1995-06-06
JPS63264532A (ja) 1988-11-01
DE3889138T2 (de) 1994-08-04
EP0279563A3 (en) 1989-10-25
JP2525734B2 (ja) 1996-08-21
GB8802507D0 (en) 1988-03-02
ES2052699T3 (es) 1994-07-16

Similar Documents

Publication Publication Date Title
DE3889138D1 (de) Influenza-Impfstoff.
KR0156732B1 (ko) 연속 셀 라인에서의 ibdv 생성
Stephenson et al. Antigenic relationships between measles and canine distemper viruses: comparison of immune response in animals and humans to individual virus-specific polypeptides.
MX9203458A (es) Segmentos inmunogenicos que contienen glicoproteinas quimericas de las glicoproteinas de virus sincitial respiratorio humano.
ATE46920T1 (de) Viren und impfstoffe.
Charlton et al. Skunk rabies
Henle et al. A skin test for infectious hepatitis.
Enders General preface to studies on the cultivation of poliomyelitis viruses in tissue culture
Kohl et al. Ontogeny of murine cellular cytotoxicity to herpes simplex virus-infected cells
Brugh et al. Emergence of highly pathogenic virus during selective chicken passage of the prototype mildly pathogenic chicken/Pennsylvania/83 (H5N2) influenza virus
ATE375T1 (de) Grippevirusimpfstoff und verfahren zu seiner herstellung.
Wenner et al. Propagation of group A coxsackie viruses in tissue cultures: II. Some interactions between virus and mammalian cells
Shaw Cultivation of Coxsackie virus in embryonated eggs and in chick tissue cultures
Cox The structural proteins of rabies virus
AU6258480A (en) Prep" of influenza virus strains and vaccines
DE2966648D1 (en) Vaccine against diseases caused by reo viruses, combined vaccine with newcastle disease virus, process for preparing them and reo virus strain used for their preparation
ES2060740T3 (es) Vacunas de virus vivos para la enfermedad de newcastle.
Spalatin et al. Recovery of a newcastle disease virus strain indistinguishable from Texas GB
RU2068271C1 (ru) Аттенуированный холодоадаптированный штамм вируса гриппа в/ленинград/14/17/55 для получения штаммов живой гриппозной вакцины
RU2078817C1 (ru) Аттенурованный холодоадаптированный штамм вируса гриппа, используемый для получения живой интраназальной гриппозной вакцины
Mifune et al. Susceptibility of various cell lines to rabies virus
Huang et al. Association of avian reovirus M and S genes with viral behavior in vivo. I. Viral persistence
Kaminjolo Jr et al. Isolation, cultivation and characterization of a poxvirus from some horses in Kenya
Weremowicz et al. Laboratory investigations on equine influenza during the outbreak in Poland in 1980
RU92006181A (ru) Аттенуированный холодоадаптированный штамм вируса гриппа в/ссср/60/69 для получения живой интраназальной гриппозной вакцины